About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...

The pharmaceutical giant said it has agreed to acquire the U.S. privately held, clinical-stage biopharmaceutical company to ...

Johnson & Johnson is contributing $1 million to support the development of curricula and modernization of training and lab ...

February 06, 2025--(BUSINESS WIRE)--Cadrenal Therapeutics ... therapy as well as other business development opportunities to build the Company’s pipeline. Dr. Ferguson replaces Douglas W.

Pham, Chief Executive Officer, Cadrenal Therapeutics ... therapy as well as other business development opportunities to build the Company’s pipeline, as well as advancing other indications ...

LONDON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- e-therapeutics plc, a company integrating computational power and biological data to discover ...

The platform enables direct, unbiased genome-wide identification and quantification of the exact position of double strand DNA breaks in edited cells.

Separately, Rakovina Therapeutics expects to receive the first synthesized drug candidates from its second AI-driven drug ...